A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Doxorubicin; Paclitaxel
- Indications Endometrial cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-775
- Sponsors Eisai Inc
- 09 Sep 2019 According to an Merck & Co media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress.
- 04 Jun 2019 Trial design presented at the 55th Annual meeting of American Society of Clinical Oncology.
- 01 Aug 2018 Planned End Date changed from 23 Jan 2022 to 25 Jan 2023.